Propionate metabolism and cancer
Propionate metabolism and cancer
批准号:
10660197
负责人:
JOHN BLENIS
金额:
$63.44万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-25 至 2028-03-31
关键词:
AddressAgeAreaAutomobile DrivingBiochemicalBiological MarkersBiological ProcessBiologyBranched-Chain Amino AcidsBreast Cancer CellCancer BiologyCause of DeathCellsCessation of lifeChemoresistanceCommunicationCoupledDNA Sequence AlterationDataDevelopmentDicarboxylic AcidsDiseaseDisseminated Malignant NeoplasmDrug TargetingDrug resistanceElderlyEnzymesEpigenetic ProcessEpithelial CellsExpression ProfilingFatty AcidsFibroblastsGene ExpressionGeneticGenetic TranscriptionGoalsHereditary DiseaseHypoxiaIn VitroInborn Errors of MetabolismKnowledgeLinkMAPK1 geneMalignant NeoplasmsMesenchymalMetabolicMetabolic PathwayMetabolic dysfunctionMetabolismMethylmalonic AcidMethylmalonyl-CoA MutaseMolecularNeoplasm MetastasisOncologyPathway interactionsPatientsPersonsPhenotypePhysiological ProcessesPrimary NeoplasmProcessProductionPropertyPropionatesProteomicsPublishingRegulator GenesSerumSignal TransductionSolid NeoplasmTestingTherapeutic InterventionTimeTumor PromotionWorkage relatedautocrinecancer cellcancer therapydrug discoveryepimeraseepithelial to mesenchymal transitionexpectationextracellularimprovedin vivoin vivo Modelinsightlung cancer cellmetabolomemetabolomicsmethylmalonic aciduriamethylmalonyl-CoA decarboxylasemethylmalonyl-coenzyme Amortalityneoplastic cellnon-geneticnovelnutrient deprivationparacrinepersonalized therapeuticpreventprogramspropionyl-coenzyme Atargeted treatmenttherapeutic targettranscriptomicstumortumor growthtumor microenvironmenttumor progressionwound healing
中文摘要
SUMMARY(最多30行)
英文摘要
SUMMARY (30 lines max)
The vast majority of cancer mortality is due to metastases. A major unmet need in oncology is how to predict
and prevent metastatic progression. To address this need, it is imperative we advance our understanding of how
tumor cells acquire metastatic capability. Epithelial-to-mesenchymal transition (EMT) is a normal physiologic
process in wound healing and development by which polarized epithelial cells undergo biochemical, metabolic,
and epigenetic changes and convert to a mesenchymal phenotype, characterized by enhanced migratory and
invasive capacity. Cancers co-opt this reprogramming to acquire metastatic ability. Understanding how tumor
cells undergo EMT is critical to unraveling how cancer becomes metastatic. Historically, studies have primarily
focused on genetic mutations or gene expression changes that trigger EMT and metastasis. But recent work has
suggested that non-genetic factors such as metabolites can promote cancer progression, suggesting unexplored
areas of cancer biology. To gain a deeper understanding of EMT and capture the sequential changes necessary
for cancer to become metastatic, we performed proteomics, metabolomics and transcriptomics at multiple time
points as cells underwent EMT. Our multifaceted approach revealed rich new insights. We found that propionate
metabolism was dysregulated during EMT. Indeed, we observed increased propionyl-CoA and methylmalonic
acid (MMA), a dicarboxylic acid by-product of propionate metabolism, during early EMT. To test the functional
effect of elevated MMA, we treated lung and breast cancer cells with MMA. Strikingly, we found that MMA
triggered EMT and enhanced migratory and invasive capacity. Prior to our discovery, little was known about
propionate metabolism and MMA other than propionate metabolism is dysregulated in rare inborn errors of
metabolism collectively referred to as “methylmalonic acidemias.” Some recent studies have also shown that
MMA increases in serum with age and is linked to age-related, all-cause mortality. To our knowledge, our findings
are the first to demonstrate that propionate metabolism plays a role in EMT and cancer cell progression. This
led us to study how propionate metabolism is altered during EMT. Our long-term goals are to define how this
pathway is regulated by multiple inducers of metastasis and at multiple points in the pathway, and to define how
MMA produced by cancer cells can also influence the tumor microenvironment. Our proposed studies will
address a critical need for a greater understanding of the molecular basis of metastasis. Our expectations are
that successful completion of the proposed work will impact cancer biology by shifting the paradigm and
highlighting critical non-genetic factors that drive cancer progression. Consequently, our work will identify new
biomarkers and therapeutic targets that can be exploited to prevent and inhibit metastases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of NAGK cysteine deprotonation in nutrient stress and cancer progression
-
批准号:10652823
-
项目类别:
-
资助金额:$8.48万
-
财政年份:2023
-
负责人:JOHN BLENIS
-
依托单位:
Molecular and Translational Oncology Research
-
批准号:9280411
-
项目类别:
-
资助金额:$27.23万
-
财政年份:2017
-
负责人:JOHN BLENIS
-
依托单位:
Molecular and Translational Oncology Research
-
批准号:10202497
-
项目类别:
-
资助金额:$28.53万
-
财政年份:2017
-
负责人:JOHN BLENIS
-
依托单位:
Molecular and biochemical basis of Lymphangioleiomyomatosis
-
批准号:8612928
-
项目类别:
-
资助金额:$49.81万
-
财政年份:2014
-
负责人:JOHN BLENIS
-
依托单位:
Molecular and biochemical basis of Lymphangioleiomyomatosis
-
批准号:8788716
-
项目类别:
-
资助金额:$49.51万
-
财政年份:2014
-
负责人:JOHN BLENIS
-
依托单位:
Molecular and biochemical basis of Lymphangioleiomyomatosis
-
批准号:9197682
-
项目类别:
-
资助金额:$50.27万
-
财政年份:2014
-
负责人:JOHN BLENIS
-
依托单位:
FASEB Conference on Protein Kinases
-
批准号:7331403
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2007
-
负责人:JOHN BLENIS
-
依托单位:
Development of a high content cell based screen for inhibitors of the mTOR signal
-
批准号:7680763
-
项目类别:
-
资助金额:$4.23万
-
财政年份:2007
-
负责人:JOHN BLENIS
-
依托单位:
FASEB Conference on Protein Kinases
-
批准号:7457859
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2007
-
负责人:JOHN BLENIS
-
依托单位:
Development of a high content cell based screen for inhibitors of the mTOR signal
-
批准号:7290648
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2007
-
负责人:JOHN BLENIS
-
依托单位:
MOLECULAR AND GENETIC BASIS OF CELL PROLIF--GORDON CONF
-
批准号:2370780
-
项目类别:
-
资助金额:$0.4万
-
财政年份:1997
-
负责人:JOHN BLENIS
-
依托单位:
SIGNAL TRANSDUCTION TO P70 S6 KINASE 1
-
批准号:6386067
-
项目类别:
-
资助金额:$46.32万
-
财政年份:1995
-
负责人:JOHN BLENIS
-
依托单位:
SIGNAL TRANSDUCTION TO P70 S6 KINASE 1
-
批准号:6878608
-
项目类别:
-
资助金额:$56.64万
-
财政年份:1995
-
负责人:JOHN BLENIS
-
依托单位:
Signal Transduction to P70 S6 Kinase 1
-
批准号:8956533
-
项目类别:
-
资助金额:$22.5万
-
财政年份:1995
-
负责人:JOHN BLENIS
-
依托单位:
Signal Transduction to p70 S6 Kinase 1
-
批准号:7463029
-
项目类别:
-
资助金额:$57.54万
-
财政年份:1995
-
负责人:JOHN BLENIS
-
依托单位:
Signal Transduction to p70 S6 Kinase 1
-
批准号:7764664
-
项目类别:
-
资助金额:$64.57万
-
财政年份:1995
-
负责人:JOHN BLENIS
-
依托单位:
SIGNAL TRANSDUCTION TO PP70 S6K
-
批准号:2189911
-
项目类别:
-
资助金额:$17.28万
-
财政年份:1995
-
负责人:JOHN BLENIS
-
依托单位:
SIGNAL TRANSDUCTION TO PP70 S6K
-
批准号:2189912
-
项目类别:
-
资助金额:$16.85万
-
财政年份:1995
-
负责人:JOHN BLENIS
-
依托单位:
SIGNAL TRANSDUCTION TO P70 S6 KINASE 1
-
批准号:7218114
-
项目类别:
-
资助金额:$56.96万
-
财政年份:1995
-
负责人:JOHN BLENIS
-
依托单位:
SIGNAL TRANSDUCTION TO P70 S6 KINASE 1
-
批准号:7037418
-
项目类别:
-
资助金额:$56.96万
-
财政年份:1995
-
负责人:JOHN BLENIS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: